Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 6/20 | 0.68 |
| ▸ | HTR2A | P28223 | 5/20 | 0.68 |
| ▸ | DRD1 | P21728 | 4/20 | 0.68 |
| ▸ | HTR2C | P28335 | 4/20 | 0.68 |
| ▸ | HRH1 | P35367 | 4/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 4/20 | 0.57 |
| ▸ | HTR7 | P34969 | 4/20 | 0.57 |
| ▸ | DRD4 | P21917 | 3/20 | 0.57 |
| ▸ | HRH2 | P25021 | 3/20 | 0.57 |
| ▸ | HTR1B | P28222 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024823 | 1.00 | HTR2B (0.68) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL29356737 | 0.81 | HTR2B (1.00) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL13701277 | 0.81 | HTR2B (1.00) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL30543449 | 0.81 | HTR2B (1.00) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL675164 | 0.81 | HTR2B (1.00) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL4227186 | 0.81 | HTR2B (1.00) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL340674 | 0.81 | HTR2B (1.00) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL8008450 | 0.81 | HTR2B (0.90) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL8008033 | 0.81 | HTR2B (0.89) | HTR2BHTR2ADRD1HTR2CHRH1 | |
| Volinanserin SCHEMBL29899671 | 0.80 | HTR2B (0.98) | HTR2BHTR2ADRD1HTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | ADRM1, CYP2E1, OPRD1 | HTR2B 1333/4885HTR2A 1470/4885DRD1 41/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | HTR2B 1312/4885HTR2A 1477/4885DRD1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.